JPS54148739A - Substituted propanolamine and morpholine derivative - Google Patents

Substituted propanolamine and morpholine derivative

Info

Publication number
JPS54148739A
JPS54148739A JP449479A JP449479A JPS54148739A JP S54148739 A JPS54148739 A JP S54148739A JP 449479 A JP449479 A JP 449479A JP 449479 A JP449479 A JP 449479A JP S54148739 A JPS54148739 A JP S54148739A
Authority
JP
Japan
Prior art keywords
morpholine derivative
substituted
substituted propanolamine
morpholine
propanolamine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP449479A
Other languages
English (en)
Japanese (ja)
Other versions
JPS6331455B2 (enExample
Inventor
Merurooni Piero
Derura Torure Arutsuro
Kuraudeio Karunieru Jiyobuanni
Rotsushi Aretsusandoro
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Italia SRL
Original Assignee
Carlo Erba SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IT1945078A external-priority patent/IT1111676B/it
Priority claimed from IT1944978A external-priority patent/IT1093255B/it
Priority claimed from IT3053478A external-priority patent/IT1160302B/it
Priority claimed from IT3053378A external-priority patent/IT1160301B/it
Priority claimed from IT30535/78A external-priority patent/IT1101724B/it
Application filed by Carlo Erba SpA filed Critical Carlo Erba SpA
Publication of JPS54148739A publication Critical patent/JPS54148739A/ja
Publication of JPS6331455B2 publication Critical patent/JPS6331455B2/ja
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/27—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups
    • C07C205/32—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups bound to acyclic carbon atoms and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/27—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups
    • C07C205/35—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C205/36—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton to carbon atoms of the same non-condensed six-membered aromatic ring or to carbon atoms of six-membered aromatic rings being part of the same condensed ring system
    • C07C205/37—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton to carbon atoms of the same non-condensed six-membered aromatic ring or to carbon atoms of six-membered aromatic rings being part of the same condensed ring system the oxygen atom of at least one of the etherified hydroxy groups being further bound to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C41/00—Preparation of ethers; Preparation of compounds having groups, groups or groups
    • C07C41/01—Preparation of ethers
    • C07C41/16—Preparation of ethers by reaction of esters of mineral or organic acids with hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/41—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by hydrogenolysis or reduction of carboxylic groups or functional derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C07D265/32—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings with oxygen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C07D265/32—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings with oxygen atoms directly attached to ring carbon atoms
    • C07D265/33—Two oxygen atoms, in positions 3 and 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/18—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
    • C07D303/20—Ethers with hydroxy compounds containing no oxirane rings
    • C07D303/24—Ethers with hydroxy compounds containing no oxirane rings with polyhydroxy compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/58—Radicals substituted by nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP449479A 1978-01-20 1979-01-20 Substituted propanolamine and morpholine derivative Granted JPS54148739A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IT1945078A IT1111676B (it) 1978-01-20 1978-01-20 Derivati della 2-fenossimetil-morfolina
IT1944978A IT1093255B (it) 1978-01-20 1978-01-20 Derivati fenossialcanolaminici
IT3053478A IT1160302B (it) 1978-12-05 1978-12-05 Derivati della 2-fenossimentil-morfolina
IT3053378A IT1160301B (it) 1978-12-05 1978-12-05 Derivati fenossialcanolaminici
IT30535/78A IT1101724B (it) 1978-12-05 1978-12-05 Derivati morfolinici e fenossiprofanolaminici e procedimento per la loro preparazione

Publications (2)

Publication Number Publication Date
JPS54148739A true JPS54148739A (en) 1979-11-21
JPS6331455B2 JPS6331455B2 (enExample) 1988-06-23

Family

ID=27517788

Family Applications (1)

Application Number Title Priority Date Filing Date
JP449479A Granted JPS54148739A (en) 1978-01-20 1979-01-20 Substituted propanolamine and morpholine derivative

Country Status (24)

Country Link
US (2) US4229449A (enExample)
JP (1) JPS54148739A (enExample)
AT (1) AT371813B (enExample)
AU (1) AU525954B2 (enExample)
BG (1) BG61056B2 (enExample)
CA (1) CA1128942A (enExample)
CH (1) CH650245A5 (enExample)
CS (1) CS413391A3 (enExample)
CY (1) CY1172A (enExample)
DE (2) DE19875005I2 (enExample)
DK (1) DK156565C (enExample)
FI (1) FI71135C (enExample)
FR (2) FR2442839A1 (enExample)
GB (1) GB2014981B (enExample)
HK (1) HK5783A (enExample)
IE (1) IE47727B1 (enExample)
IL (1) IL56369A (enExample)
KE (1) KE3243A (enExample)
MY (1) MY8400018A (enExample)
NO (1) NO146953C (enExample)
NZ (1) NZ189418A (enExample)
SE (1) SE446727B (enExample)
SI (1) SI7910096A8 (enExample)
YU (1) YU42094B (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55108649A (en) * 1978-11-17 1980-08-21 Energy Conversion Devices Inc Printing device
JPS61129174A (ja) * 1984-11-22 1986-06-17 フアーミタリア・カルロ・エルバ・ソシエタ・ペル・アツイオーニ ベンジルモルホリンのフエノキシ誘導体の鏡像異性体およびその塩
JP2008019267A (ja) * 2004-04-30 2008-01-31 Warner-Lambert Co Llc 中枢神経系障害治療用の置換モルホリン化合物
JP2008106070A (ja) * 2004-04-30 2008-05-08 Pfizer Inc 新規化合物
JP2011525497A (ja) * 2008-06-23 2011-09-22 中国人民解放軍軍事医学科学院毒物薬物研究所 アミン化合物及びそれを含有する医薬組成物

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2162517B (en) * 1984-08-01 1988-04-27 Erba Farmitalia Process for the preparation of 3-substituted derivatives of 1-amino-2-hydroxy-propane
GB8419683D0 (en) * 1984-08-02 1984-09-05 Erba Farmitalia 3-substituted derivatives of 1-amino-2-hydroxy-propane
DE3546929B4 (de) * 1984-08-02 2006-02-09 Pharmacia Italia S.P.A. 1,2-substituierte Derivate von 3-Phenoxy-3-Phenylpropan
GB8823405D0 (en) * 1988-10-05 1988-11-09 Erba Carlo Spa Aryloxy-arythio-heteraryloxy-heteroarylthio-alkenylene derivatives of amines
FR2754709B1 (fr) 1996-10-23 1999-03-05 Sanofi Sa Composition cosmetique contenant un antagoniste des recepteurs du neuropeptide gamma et alpha 2 antagonistes susceptibles d'etre incorpores dans une telle composition
AU9214498A (en) * 1997-09-23 1999-04-12 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
UA56257C2 (uk) * 1997-09-23 2003-05-15 Елі Ліллі Енд Компані Спосіб лікування неадекватної визивної поведінки
US6586427B2 (en) * 1998-04-09 2003-07-01 Pharmacia & Upjohn Company Treatments for nervous disorders
CN1301164A (zh) 1998-04-09 2001-06-27 法玛西雅厄普约翰美国公司 神经病症的新疗法
IT1305322B1 (it) * 1998-04-23 2001-05-04 Pharmacia & Upjohn Spa Uso di reboxetina per il trattamento di disturbi nervosi
US6500827B2 (en) * 1998-05-08 2002-12-31 Pharmacia & Upjohn Company Drug combinations
TR200101885T2 (tr) 1998-12-29 2002-01-21 Pharmacia & Upjohn Company Aril eterler hazırlamak için yöntem.
EP1459750B1 (en) * 1999-07-01 2005-06-01 Pharmacia & Upjohn Company LLC (S,S)-reboxetine for treating fibromyalgia and other somatoform disorders
AU2005220235B2 (en) * 1999-07-01 2007-05-10 Pharmacia & Upjohn Company Selective norepinephrine reuptake inhibitors and methods of using the same
JP2003503450A (ja) * 1999-07-01 2003-01-28 ファルマシア・アンド・アップジョン・カンパニー 高選択的ノルエピネフリン再取込みインヒビターおよびその使用方法
US6387403B1 (en) 1999-09-15 2002-05-14 Alza Corporation Dosage forms and methods for providing effective reboxetine therapy with once-a-day dosing
US20040048860A1 (en) * 2000-10-31 2004-03-11 Jes Olesen Use of selective noradrenaline reuptake inhibitors for the treatment of tension-type headache
US20040034106A1 (en) * 2001-11-06 2004-02-19 Read Holly Ann Treatment of anxiety disorders
AU2002347984A1 (en) * 2001-11-30 2003-06-17 Eli Lilly And Company Use of norepinephrine reuptake inhibitors for the treatment of tic disorders
MXPA04009352A (es) * 2002-04-18 2005-01-25 Pharmacia Corp Terapia de combinacion para el tratamiento de la enfermedad de parkinson con inhibidores de ciclooxigenasa-2 (cox2).
CA2495452A1 (en) * 2002-08-14 2004-02-26 Pharmacia & Upjohn Company Llc Use of reboxetine for the treatment of hot flashes
US20040220153A1 (en) * 2002-09-24 2004-11-04 Jost-Price Edward Roydon Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
US20040229849A1 (en) * 2002-09-24 2004-11-18 Jost-Price Edward Roydon Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
US7345096B2 (en) * 2002-10-15 2008-03-18 Wyeth Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms
US20040152710A1 (en) * 2002-10-15 2004-08-05 Deecher Darlene Coleman Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms
US7417064B2 (en) * 2002-11-05 2008-08-26 Eli Lilly And Company 3-aryloxy/thio-3-substituted propanamines and their use in inhibiting serotonin and norepinephrine reuptake
MY143244A (en) 2002-11-26 2011-04-15 Smithkline Beecham Corp Calcilytic compounds
US20040204411A1 (en) * 2002-12-17 2004-10-14 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of reboxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
EP1620083A2 (en) * 2003-04-18 2006-02-01 Pharmacia & Upjohn Company LLC Combination therapies
US20060100290A1 (en) * 2003-07-28 2006-05-11 Dunaway Leslie J Treatment of allergic rhinitis and asthma
WO2005025675A1 (en) 2003-09-12 2005-03-24 Pfizer Limited Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors
EP1675582A1 (en) * 2003-09-12 2006-07-05 Warner-Lambert Company LLC Combination comprising an alpha-2-delta ligand and an ssri and/or snri for treatment of depression and anxiety disorders
US7365076B2 (en) * 2003-10-14 2008-04-29 Wyeth Substituted aryl cycloalkanol derivatives and methods of their use
US7402698B2 (en) * 2003-10-14 2008-07-22 Wyeth Secondary amino-and cycloamino-cycloalkanol derivatives and methods of their use
US7550485B2 (en) * 2003-10-14 2009-06-23 Wyeth Substituted N-heterocycle derivatives and methods of their use
US20050130987A1 (en) * 2003-10-14 2005-06-16 Wyeth Methods of treating vasomotor symptoms
US7491723B2 (en) * 2003-10-14 2009-02-17 Wyeth Alkanol and cycloalkanol-amine derivatives and methods of their use
US7531543B2 (en) * 2003-10-14 2009-05-12 Wyeth Phenylpiperazine cycloalkanol derivatives and methods of their use
US7419980B2 (en) * 2003-10-14 2008-09-02 Wyeth Fused-aryl and heteroaryl derivatives and methods of their use
US7524846B2 (en) * 2003-10-14 2009-04-28 Wyeth Arylalkyl- and cycloalkylalkyl-piperazine derivatives and methods of their use
EP2343073A3 (en) 2003-12-11 2011-10-12 Sepracor Inc. Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
WO2005082869A1 (en) * 2004-02-20 2005-09-09 Pharmacia & Upjohn Company Llc Method for the preparation of aryl ethers
JP2007523153A (ja) * 2004-02-20 2007-08-16 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー アリールエーテルの製造方法
US7517899B2 (en) * 2004-03-30 2009-04-14 Wyeth Phenylaminopropanol derivatives and methods of their use
US7414052B2 (en) * 2004-03-30 2008-08-19 Wyeth Phenylaminopropanol derivatives and methods of their use
AU2006239922A1 (en) * 2005-04-22 2006-11-02 Wyeth Benzofuranyl alkanamine derivatives and uses thereof as 5-HT2c agonists
WO2006116150A1 (en) 2005-04-22 2006-11-02 Wyeth Dihydrobenzofuran derivatives and uses thereof
EP2317316A3 (en) 2005-07-08 2011-06-15 Braincells, Inc. Methods for identifying agent and conditions that modulate neurogenesis
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
JP2009512711A (ja) 2005-10-21 2009-03-26 ブレインセルス，インコーポレイティド Ｐｄｅ阻害による神経新生の調節
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
JP2009531435A (ja) * 2006-03-24 2009-09-03 ワイス うつ病の治療用の新規な治療組み合わせ
US20080020387A1 (en) * 2006-03-31 2008-01-24 Lawrence Donald G Biomarker-optimized adhd treatment
EP2382975A3 (en) 2006-05-09 2012-02-29 Braincells, Inc. Neurogenesis by modulating angiotensin
CA2651862A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
WO2008019431A1 (en) * 2006-08-14 2008-02-21 Brc Operations Pty Limited Method and compositions for simultaneously regulating memory and mood
JP2010502722A (ja) 2006-09-08 2010-01-28 ブレインセルス，インコーポレイティド ４−アシルアミノピリジン誘導体を含む組み合わせ
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
DK2076508T3 (da) 2006-10-18 2011-02-21 Pfizer Prod Inc Biaryl-ether-urinstof-forbindelser
WO2008122019A1 (en) * 2007-04-02 2008-10-09 Cypress Biosciences, Inc. Improving the tolerability of both mirtazapine and reboxetine by using them in combination
JP5405571B2 (ja) 2008-07-24 2014-02-05 セラヴァンス， インコーポレーテッド ３−（フェノキシフェニルメチル）ピロリジン化合物
US20100069389A1 (en) * 2008-09-06 2010-03-18 Bionevia Pharmaceuticals, Inc. Novel forms of reboxetine
MX2011005089A (es) 2008-11-14 2011-07-29 Theravance Inc Compuestos de 4-[2-(2-fluorofenoximetil)fenil]piperidina.
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
WO2010120910A1 (en) * 2009-04-15 2010-10-21 Theravance, Inc. 3-(phenoxypyrrolidin-3-yl-methyl)heteroaryl, 3-(phenylpyrrolidin-3-ylmethoxy)heteroaryl, and 3-(heteroarylpyrrolidin-3-ylmethoxy)heteroaryl compounds
RU2535669C2 (ru) * 2009-07-13 2014-12-20 Тереванс, Инк. 3-феноксиметилпирролидиновые соединения
JP5714580B2 (ja) 2009-07-21 2015-05-07 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー ３−フェノキシメチルピロリジン化合物
WO2011085291A1 (en) * 2010-01-11 2011-07-14 Theravance, Inc. 1 - (2 - phenoxymethylphenyl) piperazine compounds as serotonin and norepinephrine reuptake inhibitors
ES2543064T3 (es) * 2010-03-22 2015-08-14 Theravance Biopharma R&D Ip, Llc Compuestos de 1-(2-fenoximetilheteroaril)piperidina y piperazina
WO2012051103A1 (en) 2010-10-11 2012-04-19 Theravance, Inc. Serotonin reuptake inhibitors
WO2012075239A1 (en) 2010-12-03 2012-06-07 Theravance, Inc. Serotonin reuptake inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1138405A (en) * 1966-12-28 1969-01-01 Ici Ltd Morpholine derivatives
BE759013R (fr) * 1969-11-17 1971-05-17 Ici Ltd Derives de la
GB1382526A (en) * 1972-08-11 1975-02-05 Ici Ltd Morpholine derivatives
GB1412546A (en) * 1973-08-08 1975-11-05 Ici Ltd Morpholine derivatives
GB1427097A (en) * 1973-10-18 1976-03-03 Ici Ltd Optically-active morpholine derivatives
GB1469410A (en) * 1973-12-17 1977-04-06 Christiaens Sa A Benzodioxole derivatives
US4314081A (en) * 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines
GB1576216A (en) * 1975-01-29 1980-10-01 Yamanouchi Pharma Co Ltd 2-(7-indenyloxymethyl)-morpholine derivatives and process of producing them
CA1064927A (en) * 1975-01-29 1979-10-23 Yuji Kawashima Process of producing 2-(indenyloxymethyl) morpholine derivatives
CA1085841A (en) * 1976-05-19 1980-09-16 Jean-Marie Ferland Aryloxy proplamines, their preparation and use thereof

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55108649A (en) * 1978-11-17 1980-08-21 Energy Conversion Devices Inc Printing device
JPS61129174A (ja) * 1984-11-22 1986-06-17 フアーミタリア・カルロ・エルバ・ソシエタ・ペル・アツイオーニ ベンジルモルホリンのフエノキシ誘導体の鏡像異性体およびその塩
JP2008019267A (ja) * 2004-04-30 2008-01-31 Warner-Lambert Co Llc 中枢神経系障害治療用の置換モルホリン化合物
JP2008106070A (ja) * 2004-04-30 2008-05-08 Pfizer Inc 新規化合物
JP2011525497A (ja) * 2008-06-23 2011-09-22 中国人民解放軍軍事医学科学院毒物薬物研究所 アミン化合物及びそれを含有する医薬組成物

Also Published As

Publication number Publication date
US4229449A (en) 1980-10-21
FI790177A7 (fi) 1979-07-21
DK156565B (da) 1989-09-11
AU525954B2 (en) 1982-12-09
CH650245A5 (de) 1985-07-15
IL56369A (en) 1984-05-31
SE446727B (sv) 1986-10-06
SE7900498L (sv) 1979-07-21
FR2442839A1 (fr) 1980-06-27
CA1128942A (en) 1982-08-03
YU9679A (en) 1983-12-31
US4271160A (en) 1981-06-02
FR2430412B1 (fr) 1987-06-26
AT371813B (de) 1983-08-10
GB2014981B (en) 1982-08-11
DK156565C (da) 1990-02-05
YU42094B (en) 1988-04-30
DE2901032C2 (de) 1996-05-30
ATA40679A (de) 1982-12-15
GB2014981A (en) 1979-09-05
CY1172A (en) 1983-06-10
KE3243A (en) 1982-12-03
NZ189418A (en) 1981-03-16
MY8400018A (en) 1984-12-31
FR2430412A1 (fr) 1980-02-01
IE790107L (en) 1979-07-20
FI71135C (fi) 1986-11-24
SI7910096A8 (sl) 1996-10-31
AU4332779A (en) 1979-07-26
CS413391A3 (en) 1992-05-13
JPS6331455B2 (enExample) 1988-06-23
DE19875005I2 (de) 2002-10-24
BG61056B2 (bg) 1996-09-30
DK22679A (da) 1979-07-21
FI71135B (fi) 1986-08-14
NO790205L (no) 1979-07-23
HK5783A (en) 1983-02-08
NO146953C (no) 1983-01-05
IL56369A0 (en) 1979-03-12
DE2901032A1 (de) 1979-08-02
FR2442839B1 (enExample) 1984-07-27
NO146953B (no) 1982-09-27
IE47727B1 (en) 1984-05-30

Similar Documents

Publication Publication Date Title
GB2014981B (en) Substituted propanolamine and morpholine derivatives
SE8503680L (sv) Indolderivat
DE3168037D1 (en) Rhodanine derivatives, process for their preparation, and aldose reductase inhibitor containing the rhodanine derivatives as active ingredient
IT1264451B1 (it) 3-(carbossimetossifenil)-benzofuran-2-oni come agenti stabilizzanti
NL8103768A (nl) Heterocyclische verbindingen, werkwijze ter bereiding daarvan, alsmede farmaceutische preparaten die deze verbindingen als actieve component bevatten.
DE3868076D1 (de) Heterocyclische derivate, verfahren zu ihrer herstellung und diese derivate als aktive bestandteile enthaltende fungizide.
SE8302693L (sv) Heterocykliska foreningar
AU536920B2 (en) Hydroxypropyl-triazole derivatives and their use as antimycotic agents
IT1190824B (it) Composizione farmaceutica contenente 24,25-diidrossicolecalciferolo come ingrediente attivo
IE43951L (en) 1-benzazolylalkyl-4-substituted-piperdines
IL56413A (en) Substituted heterocyclic benzamides,their preparation and pharmaceutical compositions containing them
BG31473A3 (en) Fungicide means and method for fungus fighting
ES2018208B3 (es) Derivados de hidroxipirazol, procedimiento para su obtencion y su aplicacion contra microorganismos.
NO960826L (no) Anvendelse av enzymer fra krill i forstoffer
DE3382578D1 (de) Ester aus 3-(3-substituierten amino-2-hydroxypropoxy)-4-substituierten 2,5-thiadiazolabkoemmlingen.
ES482438A0 (es) Procedimiento para la preparacion de nuevos derivados de 2-(4-aminopiperidino)-3,4-dihidroquinoleina.
FI890864A0 (fi) Anvaendning av 1,4-dihydropyridinderivat.
IT1113373B (it) Derivati del 1,5-dimetilbiciclo(3.2.1.)-ottano,preparazione di questi composti e loro impiego come composti per profumi
IT8122397A0 (it) Derivati di 3-aril- e 3-eterociclil-2,3-diidro-1,4-benzossazina.
ES517874A0 (es) Procedimiento de preparacion de derivados de diaza-3,7a-cicloherta-(j,k)-fluorenos.
DK164165C (da) Thiochromanderivater, fremgangsmaade til fremstilling deraf samt et farmaceutisk middel indeholdende derivatet
NO153172C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive decarboxylaseinhiberende fluorerte alkandiaminderivater.
FI813776A7 (fi) Amino-penisilliini-johdannainen, menetelmä sen valmistamiseksi, terapeuttisia seoksia, jotka sisältävätsitä vaikuttavana aineosanaan.
FI810089A7 (fi) Uusia heterosyklisiä yhdisteitä, joita käytetään allergiavastaisina aineina.
IT8024108A0 (it) Derivati del2-solfinil-5-solfonil-1,3,4-tiadiazolo, procedimento per la fabbricazione di questi composti nonche' mezzi fungicidi che licontengono.